PM

Paul Mollard

PT Ptc Therapeutics: 11 patents #27 of 160Top 20%
EP Edison Pharmaceuticals: 9 patents #3 of 24Top 15%
BT Bioelectron Technology: 5 patents #1 of 14Top 8%
CN CNRS: 4 patents #613 of 11,908Top 6%
PK Produits Chimiques Uging Kuhlmann: 2 patents #15 of 118Top 15%
US Universite Paul Sabatier: 1 patents #14 of 53Top 30%
UI Universite Paul Sabatier—Toulouse Iii: 1 patents #95 of 378Top 30%
UP Uranium Pechiney: 1 patents #5 of 25Top 20%
📍 Saratoga, CA: #299 of 2,933 inventorsTop 15%
🗺 California: #15,031 of 386,348 inventorsTop 4%
Overall (All Time): #106,434 of 4,157,543Top 3%
33
Patents All Time

Issued Patents All Time

Showing 1–25 of 33 patents

Patent #TitleCo-InventorsDate
11938101 Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi, Christopher R. Cornell, Kieron E. Wesson 2024-03-26
11840497 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Orion D. Jankowski, Kieron E. Wesson, William D. Shrader 2023-12-12
11746077 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Andrew W. Hinman, Charles R. Holst, Angela Minnella, Sean Pintchovski, Jeffrey K. Trimmer +1 more 2023-09-05
11667596 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Andrew W. Hinman, Charles R. Holst, Angela Minnella, Sean Pintchovski, Jeffrey K. Trimmer +1 more 2023-06-06
11560364 Methods for enriching alpha-tocotrienol from mixed tocol compositions Peter Giannousis, Noah Benjamin, Jeffrey D. BUTLER, Olivier Dapremont, James B. Falabella 2023-01-24
11304914 Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi 2022-04-19
11186559 Methods for enriching alpha-tocotrienol from mixed tocol compositions Peter Giannousis, Noah Benjamin, Jeffrey D. BUTLER, Olivier Dapremont, James B. Falabella 2021-11-30
11174212 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Andrew W. Hinman, Charles R. Holst, Angela Minnella, Sean Pintchovski, Jeffrey K. Trimmer +1 more 2021-11-16
10968166 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Orion D. Jankowski, Kieron E. Wesson, William D. Shrader 2021-04-06
10751302 Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi 2020-08-25
10745371 Methods for enriching alpha-tocotrienol from mixed tocol compositions Peter Giannousis, Noah Benjamin, Jeffrey D. BUTLER, Olivier Dapremont, James B. Falabella 2020-08-18
10251847 Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Christopher R. Cornell, Kieron E. Wesson, Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi 2019-04-09
10202325 Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols 2019-02-12
10167251 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Orion D. Jankowski, Kieron E. Wesson, William D. Shrader 2019-01-01
10029971 Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols 2018-07-24
9932286 Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers Guy M. Miller, Sidney Hecht, Orion D. Jankowski, Kieron E. Wesson 2018-04-03
9567279 Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols 2017-02-14
9546132 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Orion D. Jankowski, Kieron E. Wesson, William D. Shrader 2017-01-17
9464016 Catechol derivatives for treatment of oxidative stress diseases Gloria Pfister 2016-10-11
9278085 Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers Guy M. Miller, Sidney Hecht, Orion D. Jankowski, Kieron E. Wesson 2016-03-08
9169196 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Orion D. Jankowski, Kieron E. Wesson, William D. Shrader 2015-10-27
9162957 Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols 2015-10-20
8716527 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases Andrew W. Hinman, Kieron E. Wesson, Orion D. Jankowski, William D. Shrader, Christopher R. Cornell 2014-05-06
8519001 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Orion D. Jankowski, Kieron E. Wesson, William D. Shrader 2013-08-27
7968746 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Orion D. Jankowski, Kieron E. Wesson, William D. Shrader 2011-06-28